News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

GlaxoSmithKline (GSK) Submits New Application for Synflorix in EU



9/18/2012 7:44:11 AM

GlaxoSmithKline PLC (GSK.LN), a research-based pharmaceutical and healthcare company, said Monday it has submitted a regulatory application in the European Union, or E.U., seeking approval of an additional indication for Synflorix(TM), a paediatric pneumococcal vaccine, for the active immunization against pneumonia caused by Streptococcus pneumoniae in infants and children from six weeks up to five years of age. Application was submitted as a variation to the Marketing Authorization Application to the European Medicines Agency.



comments powered by Disqus
   
Pneumonia

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES